PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
View/ Open
Date
2018-08-01Author
Dillon, MT
Boylan, Z
Smith, D
Guevara, J
Mohammed, K
Peckitt, C
Saunders, M
Banerji, U
Clack, G
Smith, SA
Spicer, JF
Forster, MD
Harrington, KJ
Type
Journal Article
Metadata
Show full item recordAbstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Research team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Targeted Therapy
Language
eng
Date accepted
2018-06-06
License start date
2018-08
Citation
Clinical and translational radiation oncology, 2018, 12 pp. 16 - 20
Publisher
ELSEVIER IRELAND LTD